Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Yin Yang; Jianyang Wang; Wenqing Wang; Tao Zhang; Jingjing Zhao; Yu Wang; Yexiong Li; Luhua Wang; Nan Bi

doi:10.3389/fonc.2022.1007862

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Front Oncol. 2022 Aug 24:12:1007862. doi: 10.3389/fonc.2022.1007862. eCollection 2022.

Authors

Yin Yang¹, Jianyang Wang¹, Wenqing Wang¹, Tao Zhang¹, Jingjing Zhao¹, Yu Wang¹, Yexiong Li¹, Luhua Wang², Nan Bi¹

Affiliations

¹ Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.810580.].

Keywords: Limited-stage small-cell lung cancer; chemoradiotherapy; overall survival; progression-free survival; surrogate endpoint; time to progression.

Publication types

Published Erratum